Analysis of post-progression survival (PPS) of platinum-, gemcitabine-, and topotecan-treated patients with serous ovarian carcinoma expressing high CX3CR1 using KM Plotter database13 showed it was significantly lower compared to that for patients with low CX3CR1 (Supplementary Figure 9). Here, CX3CR1 is linked to ovarian serous carcinoma.